While islet cell transplants allow some diabetics to forgo daily insulin injections, those people have to take immunosuppressive drugs in order to keep the cells from being rejected. A new implant, ...

Vivani Medical, Inc. (NASDAQ:VANI), on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight ...

Company to Proceed with Phase 2 Development Program for Islatravir Subdermal Implant “We are delighted to share our early data at CROI 2021 supporting the potential for a once-yearly dosing regimen ...

Phase 1 Data Presented Today at IAS 2019 KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today results from a Phase 1 study ...

Wednesday, Vivani Medical Inc (NASDAQ:VANI) released preclinical data on weight loss effects for NPM-115, the company’s miniature, twice-yearly exenatide subdermal implant under development for ...

Subdermal delivery of antiretrovirals shows promise in early trials Clinicians acknowledge that one of the main drawbacks in current HIV treatments is the problem of adherence. Findings published this ...

In modern times, a portable storage device isn't far from our possession. Either we can use the storage on our phones or tablets, or we keep a small flash drive on a keychain. Accessing the data, ...

Initiating coverage on Titan Pharmaceuticals (NASDAQ: TTNP), a company with a proprietary long-term drug delivery platform with Buy rating and common stock price target of $7.16 - $10.20. The ...

Did anyone else grow up with a parent who joked that one day, we’d forgo everything from keys to credit cards in favor of a chip in our hand? No? Just me? Well, Dad, you were right. Although not ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a Phase 1 study evaluating the safety, tolerability and ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today results from a Phase 1 study evaluating the pharmacokinetics and safety of a ...